Study evaluating the impact of a combination of inotropic support and heart rate monitoring on prognosis and stabilization rate in patients with decompensated chronic heart failure (legion)

Terapevticheskii Arkhiv

Volumn 82, Issue 3, 2010, Pages 47-52

  Arutyunov, G P ^a   Arutyunov, A G ^a   Volkov, A L ^b  

^a PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^b Infectious Diseases Hospital Two   (Russian Federation)

Author keywords

Decompensated heart failure; Ivabradine; Levosimendan; Treatment

Indexed keywords

BENZAZEPINE DERIVATIVE; CARDIOTONIC AGENT; DOPAMINE; HYDRAZONE DERIVATIVE; IVABRADINE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; FEMALE; HEART CONTRACTION; HEART FAILURE; HEART RATE; HUMAN; MALE; MIDDLE AGED; MONITORING; PATHOPHYSIOLOGY; PILOT STUDY; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SWAN GANZ CATHETER; TREATMENT OUTCOME;

BENZAZEPINES; BLOOD PRESSURE; CARDIOTONIC AGENTS; CATHETERIZATION, SWAN-GANZ; DOPAMINE; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE; HEART RATE; HUMANS; HYDRAZONES; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MYOCARDIAL CONTRACTION; PILOT PROJECTS; PROGNOSIS; PROSPECTIVE STUDIES; PYRIDAZINES; TREATMENT OUTCOME;

EID: 77952045452     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. The Task Force for the Diagnosis and Treatment of chronic Heart Failure of the European Society of cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur. Heart J. 2005; 26(11): 1115-1140.
2. Cowie M. R., Mosterd A., Wood D. A. et al. The epidemiology of heart failure. Eur. Heart J. 1997; 18: 208-225.
3. Innes C. A., Wagstaff A. J. Levosimendan: a review of its use in the management of acute decompensated heart failure. Drugs 2003 63(23): 2651-2671. (Pubitemid 37491566)
4. Munger M. A. Management of acute decompensated heart failure: treatment, controversy, and future directions. Pharmacotherapy 2006; 26(8, Pt 2): 131S-138S.
5. Remme W. J., Torp-Pedersen C., Cleland J. G. et al. Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. J. Am. Coll. Cardiol. 2007; 49(9): 963-971.
6. Nieminen M. S., Akkila J., Hasenfuss G. et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J. Am. Coll. Cardiol. 2000; 36(6): 1903-1912.
7. Fonarow G. C., Adams K. F. Jr., Abraham W. T. for the ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk Stratification for In-Hospital Mortality in Acutely Decompensated Heart Failure Classification and Regression Tree Analysis. J. A. M. A. 2005; 293: 572-580.
8. Fonarow G. G., Heywood J. T., Heidenreich P. A. et al. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am. Head J. 2007; 153(6): 1021-1028.
9. Silvers S. M., Howell J. M., Kosowsky J. M. et al American College of Emergency Physicians Clinical Policies Subcommittee. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes. Ann. Emerg. Med. 2007; 49(5): 627-669.
10. Metra M., Torp-Pedersen C, Cleland J. G. et al. COMET investigators. Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. Eur. J. Heart Fail. 2007; 9(9): 901-909.
11. Purcell H., Mach F. Heart rate as a cardiovascular risk factor potential clinical benefit with ivabradine. Rev. Med. Suisse 2007; 3(113): 1375-1375, 1381-1382.
12. Petersen J. W., Felker G. M. Inotropes in the management of acute heart failure. Crit. Care Med. 2008; 36(1; Suppl.): S106-S111.
13. Endoh M., Hori M. Acute heart failure: inotropic agents and their clinical uses. Expert Opin. Pharmacother. 2006; 7(16): 2179-2202.
14. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med. 1997; 336(8): 525-533.
15. Sukonthasarn A. Prognostic value of heart rate in cardiovascular disease. J. Med. Assoc. Thailand 2007; 90(11): 2538-2540.
16. Kudaiberdieva G, Görenek B., Timuralp B. Heart rate variability as a predictor of sudden cardiac death. Anadolu Kardiyol. Derg. 2007; 7(Suppl. 1): 68-70.
17. Thackray S., Easthaugh J., Freemantle N., Cleland J. G. F. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur. J. Heart Fail. 2002; 4: 5-529.
18. Giannakoulas G., Giannoglou G, Vassilikos V. et al. Clinical significance of acute neurohormonal response after levosimendan treatment. Am. J. Cardiol. 2006; 98(8): 1123-1124.
19. Lucab L., Ghaleh B., Colin P. et al. Free in PMC Heart rate reduction by inhibition of If or by beta-blockade has different effects on postsystolic wall thickening. Br. J. Pharmacol. 2007; 150(3): 335-341.
20. Cleland J. G, Freemantle N, Coletta A. P., Clark A. L. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur. J. Heart Fail. 2006; 8(1): 105-110.
21. Yilmaz M. B., Yalta K, Yontar C. et al. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc. Drugs Ther. 2007; 21(6): 431-435.